Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?

Therapeutic Drug Monitoring

Volumn 28, Issue 3, 2006, Pages 332-338

  Colombo, Sara ^a   Telenti, Amalio ^a   Buclin, Thierry ^a   Furrer, Hansjakob ^b   Lee, Belle L ^b   Biollaz, Jérôme ^a   Decosterd, Laurent A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cellular concentration; Nonnucleoside reverse transcriptase inhibitors; Protease inhibitors; Therapeutic drug monitoring

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33748163469     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000211807.74192.62     Document Type: Article

References (36)

1. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999;36:289-304.
2. Aarnoutse RE, Schapiro JM, Boucher CA, et al. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs. 2003;63:741-753.
3. Armbruster C, Vorbach H, Steindl F, et al. Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells. J Antimicrob Chemother 2001;47:487-490.
4. Bilello JA, Bilello PA, Stellrecht K, et al. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 1996;40:1491-1497.
5. Marzolini C, Telenti A, Buclin T, et al. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Sci Appl. 2000;740:43-58.
6. Marzolini C, Beguin A, Telenti A, et al. Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. J Chromatogr B Biomed Sci Appl. 2002;774:127-140.
7. Colombo S, Beguin A, Telenti A, et al. Intracellular measurements of the anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, efavirenz, and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 2005;819:259-276.
8. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986;83:8333-8337.
9. Jones K, Hoggard PG, Sales SD, et al. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS. 2001;15:675-681.
10. Jones K, Hoggard PG, Khoo S, et al. Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. Br J Clin Pharmacol. 2001;51:99-102.
11. Khoo SH, Hoggard PG, Williams I, et al. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother. 2002;46:3228-3235.
12. Chaillou S, Durant J, Garraffo R, et al. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trials. 2002;3:493-501.
13. Ford J, Boffito M, Wildfire A, et al. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2388-2393.
14. Hennessy M, Clarke S, Spiers JP, et al. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. Antivir Ther. 2004;9:115-122.
15. Ford J, Cornforth D, Hoggard PG, et al. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir Ther. 2004;9:77-84.
16. Breilh D, Pellegrin I, Rouzés A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study). AIDS. 2004;18:1305-1310.
17. Azoulay S, Nevers MC, Créminon C, et al. Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:104-109.
18. Almond LM, Edirisinghe D, Dalton M, et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther. 2005;78:132-142.
19. Stormer E, von Moltke LL, Perloff MD, et al. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res. 2002;19:1038-1045.
20. Chandler B, Almond L, Ford J, et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. JAIDS 2003;33:551-556.
21. Hennessy M, Clarke S, Spiers JP, et al. Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics. Antivir Ther. 2003;8:191-198.
22. Crommentuyn KM, Mulder JW, Mairuhu AT, et al. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther. 2004;9:779-785.
23. Colombo S, Soranzo N, Rotger M, et al. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the intracellular exposure of nelfinavir in vivo. Pharmacogenet Genom. 2005;15:599-608.
24. Colombo S, Buclin T, Franc C, et al. Ritonavir boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposure. Antivir Ther. 2006;11:53-62.
25. Acosta EP, Henry K, Baken L, et al. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999;19:708-712.
26. Drusano GL, Bilello JA, Stein DS, et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis. 1998;178:360-367.
27. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS. 1999;13:2083-2089.
28. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genom. 2005;15:1-5.
29. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004;319:1322-1326.
30. Hasse B, Gunthard HF, Bleiber G, et al. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis. 2005;40:e22-e23.
31. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
32. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
33. Gonzalez DR, Nunez M, Jimenez-Nacher I, et al. Liver toxicity caused by nevirapine. AIDS. 2002;16:290-291.
34. Dailly E, Billaud E, Reliquet V, et al. No relantionship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol. 2004;60:343-348.
35. Almond LM, Boffito M, Hoggard PG, et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses. 2004;20:716-722.
36. Hoggard PG, Owen A. The mechanisms that control intracellular penetration of the HIV protease inhibitors. J Antimicrob Chemother. 2003;51:493-496.